Safety and Efficacy of Sofosbuvir Based Regimens in Treating Chronic ‎Hepatitis C Virus in Egyptian Patients: Real World Study: Single Center ‎Experience

Mohamed Abbasy,Tary Salman,Talaat Zakareya,Omkolsoum Al-Haddad,Ehab Darwiesh,Olfat Hendy,Tamer Abou Elela

doi:10.21608/aeji.2021.76041.1148

Abstract

Backgroundand study aims:Hepatitis C virus (HCV) is the main leading cause of liver disease in ‎Egypt. A new era of HCV treatment has been started with the evolution ‎of direct acting antiviral agents. Sofosbuvir (SOF)-based therapy was ‎introduced by the Egyptian ministry of health in 2014 in an attempt to ‎decrease disease burden. We aimed to evaluate efficacy and safety of ‎Sofosbuvir-based regimens in HCV Egyptian patients with compensated ‎liver disease‎. Patients and Method:‎This study was conducted in National Liver Institute, Menoufia‎University, Egypt. Seven hundred patients out of seven hundred fifty-‎eight chronic HCV patients with compensated liver disease who met the ‎inclusion criteria were included. According to treatment regimen patients ‎were divided to 4 groups; group 1 received Sofosbuvir (SOF), ‎Pegylated interferon (PEG-IFN) plus ribavirin (RBV), group 2 received ‎SOF plus RBV, group 3 received SOF and Simeprevir± RBV, group 4 ‎received SOF and Daclatasvir ±RBV‎.‎ Results:The overall SVR was 90.9%, 81.5%, 95% and 98% in groups 1, 2, 3, ‎and 4 respectively. SVR in patients with liver cirrhosis was 90.56, ‎‎79.16, 95 and 96% in the 4 groups respectively. In treatment ‎experienced patients, SVR was 86.8% in group 1, 78.3% in group 2, ‎‎100% in group 3 and 86.7% in group 4‎‎‎‎. Conclusion: Sofosbuvir plus daclatasvir with or without ribavirin is the safest ‎andmost effective SOF-based regimen in treatment of HCV Egyptian ‎patients with compensated liver disease‎‎‎‎.

Highlights

Chronic hepatitis C virus (HCV) infection is one of the most important clinical and public health problems
We aimed to evaluate efficacy and safety of Sofosbuvir-based regimens in HCV Egyptian patients with compensated liver disease
In 2015, the Center for Disease Control (CDC) estimated that 170 million people worldwide are chronically infected with HCV [1]

Summary

Introduction

Chronic hepatitis C virus (HCV) infection is one of the most important clinical and public health problems. In 2015, the Center for Disease Control (CDC) estimated that 170 million people worldwide are chronically infected with HCV [1]. About 20% of infected individuals spontaneously clear the virus without treatment, approximately 80% will develop chronic HCV infection[1]. Because patients with chronic infection are at risk of developing liver diseases including cirrhosis and liver cancer, with. The standard of care to treat HCV infection was injection of pegylated interferon (PEG-IFN) and daily ribavirin. This regimen was expensive, toxic, complicated to deliver and its cure rates were less than 50%, especially for people with cirrhosis [3]. Numerous clinical trials and clinical practice have shown thatDAAs are very effective and well tolerated[4]

Objectives

Results

Conclusion